2024 Foresight ASCO | A quick overview of the Voice of China in the field of lung cancer

Preface

The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, the annual "Oscar" of the oncology community, will be held in Chicago, USA from May 31 to June 4 local time. At this ASCO conference, the number of Chinese scholars in the field of lung cancer has reached a new high, let's take a look at what they are!

Oral presentation

Abstract: 8004

Adjuvant icotinib of 12 months or 6 months versus observation following adjuvant chemotherapy for resected EGFR-mutated stage II–IIIA non-small-cell lung cancer (ICTAN, GASTO1002): A randomized phase 3 trial.

Observation After 12 or 6 Months of Adjuvant Icotinib Versus Adjuvant Chemotherapy in Resectable EGFR-Mutated Stage II-IIIA Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase III Trial (ICTAN, GASTO1002)

Speaker: Wang Siyu (Sun Yat-sen University Cancer Center)

Abstract: 8008

A phase II randomized trial evaluating consolidative nivolumab in locally advanced non-small cell lung cancer post neoadjuvant chemotherapy plus nivolumab and concurrent chemoradiotherapy (GASTO-1091).

A Phase II Randomized Trial to Evaluate Neoadjuvant Chemotherapy in Combination With Nivolumab and Concurrent Chemoradiotherapy Following Nivolumab Consolidation in Locally Advanced NSCLC (GASTO-1091)

Speaker: Liu Hui (Sun Yat-sen University Cancer Center)

Abstract: 8009

Taiwan national lung cancer early detection program for heavy smokers and non-smokers with family history of lung cancer.

Early detection of lung cancer in non-smokers with heavy smoking and a family history of lung cancer in Taiwan

讲者:Pan-Chyr Yang(台湾大学医学院)

Abstract:8502

Sacituzumab tirumotecan (SKB264/MK-2870) in combination with KL-A167 (anti-PD-L1) as first-line treatment for patients with advanced NSCLC from the phase II OptiTROP-Lung01 study.

II期OptiTROP-Lung01研究：Sacituzumab tirumotecan（SKB264/MK-2870）联合KL-A167（抗PD-L1）作为中晚期NSCLC患者的一线治疗

Speaker: Fang Wenfeng (Sun Yat-sen University Cancer Center)

Abstract:8508

Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized, double-blind, multi-center, phase 3 trial.

Ivoximab in Combination With Chemotherapy in Patients With EGFR-Mutant Nonsquamous NSCLC Who Have Progressed on EGFR-TKI: A Randomized, Double-blind, Multicenter, Phase III Trial (HARMONi-A)

Speaker: Zhang Li (Sun Yat-sen University Cancer Center)

Clinical Science Symposium

Abstract Number: LBA8509

KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation

Phase III KRYSTAL-12 study: adagrasib versus docetaxel in treatment-experienced patients with advanced/metastatic NSCLC with KRAS G12C mutations

Speaker: Mok Shu-kam (Chinese University of Hong Kong)

Quick oral summary session

Abstract:8014

Overall survival of adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line treatment for extensive-stage small cell lung cancer.

Overall survival (OS) of adebelimab in combination with chemotherapy and sequential thoracic radiotherapy as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC)

Speaker: David Chen (Cancer Hospital of Shandong First Medical University)

Abstract: 8513

A multinational pivotal study of sunvozertinib in platinum pretreated non-small cell lung cancer with EGFR exon 20 insertion mutations: Primary analysis of WU-KONG1 study.

Suvotinib in patients with EGFR exon 20ins NSCLC who have failed platinum-based chemotherapy: preliminary results from an international multicenter registry clinical study, the WU-KONG1 study

Speaker: Yang Zhixin (National Taiwan University Cancer Center Hospital, China)

Abstract: 8520

Efficacy and safety of taletrectinib in patients with advanced or metastatic ROS1+ non–small cell lung cancer: The phase 2 TRUST-I study.

The story of ROS1 性NSCLC 者的效和安全性:II 期TRUST-I研究

Speaker: Li Wei (Shanghai Pulmonary Hospital)

Poster

Abstract: 8024

A phase II study of tislelizumab (TIS) and chemotherapy as neoadjuvant therapy for potentially resectable stage IIIA/IIIB non-small cell lung cancer (NSCLC).

替雷利珠单抗(TIS)和化疗新辅助治疗可切除的IIIA/IIIB期NSCLC的II期研究

讲者：Ting Wang

Abstract: 8027

Investigation of the role of personalized molecular residual disease in the assessment of high-risk non-small cell lung cancer (NSCLC) post-operation.cancer: A systematic review and meta-analysis of randomized clinical trials.

A study of the role of individualized MRD in the postoperative evaluation of high-risk NSCLC: a systematic review and meta-analysis of a randomized clinical trial

讲者:Yu-Heng Zhou(中山大学肿瘤防治中心)

Abstract:8044

Induction therapy with PD-1 antibody combined with platinum-based doublet chemotherapy for locally-advanced non-small cell lung cancer: A randomised controlled, open-label, phase 2 trial.

PD-1 antibody in combination with platinum-based dual chemotherapy induction therapy for locally advanced NSCLC: a randomized controlled, open-label phase II clinical trial

Speaker: Suyu Wang (Shanghai Pulmonary Hospital, Tongho University)

Abstract:8048

Final survival outcomes and exploratory biomarker analysis from the randomized, phase 2 neoSCORE trial: Two versus three cycles of neoadjuvant sintilimab plus chemotherapy for resectable non-small cell lung cancer.

Final survival outcomes and exploratory biomarker analysis in the randomized phase II neoSCORE trial: sintilimab plus neoadjuvant chemotherapy for resectable NSCLC with two versus three cycles

Speaker: Qiu Fuming (The Second Affiliated Hospital of Zhejiang University School of Medicine)

Abstract: 8054

Neoadjuvant hypofractionated radiotherapy combined with pembrolizumab plus chemotherapy for potentially resectable non-small cell lung cancer: A phase Ib study.

Hypofractionated radiotherapy plus pembrolizumab and chemotherapy neoadjuvant for resectable NSCLC: a phase Ib study

Speaker: Ding Naixin (Nanjing Medical University Cancer Hospital)

Abstract:8058

The safety and efficacy of induction chemoimmunotherapy in initially unresectable stage III non-small cell lung cancer.

Safety and efficacy of induction chemoimmunotherapy in unresectable stage III NSCLC

Speaker: Min Tang (National Geriatrics Center, Institute of Geriatrics, Chinese Academy of Medical Sciences)

Abstract:8062

Anlotinib plus docetaxel in advanced NSCLC progressing on immunotherapy: A pooled analysis of two randomized trials.

Immunotherapy progression of anlotinib in combination with docetaxel in advanced NSCLC: a pooled analysis of two randomized trials

讲者:Lin Wu

Abstract: 8065

A phase II, two-cohort study of neoadjuvant chemotherapy plus tislelizumab ± bevacizumab followed by hypofractionated radiotherapy, concurrent chemotherapy, and consolidative immunotherapy in locally advanced non-small cell lung cancer (GASTO-1086).

A Phase II Dual Cohort Study of Neoadjuvant Chemotherapy in Combination With Tislelizumab ± Bevacizumab Followed by Hypofractionated Radiotherapy with Chemotherapy and Consolidation Immunotherapy in Locally Advanced NSCLC (GASTO-1086)

Speaker: Qiu Bo (Sun Yat-sen University Cancer Center)

Description No.: 8073

Efficacy and surgical safety of sequential surgical resection after neoadjuvant chemoimmunotherapy for unresectable stage III NSCLC.

Efficacy and surgical safety of neoadjuvant chemoimmunotherapy for sequential surgical resection of unresectable stage III NSCLC

Speaker: Yana Qi (Shandong Provincial Cancer Hospital)

Abstract: 8077

Phase I trial of aurora kinase A (AURKA) inhibitor VIC-1911 plus osimertinib for TKI-resistant, EGFR-mutant non-small cell lung cancer (NSCLC).

A Phase I clinical trial of the aurora kinase A (AURKA) inhibitor VIC-1911 in combination with osimertinib in the treatment of TKI-resistant, EGFR-mutant NSCLC

Speaker: Shen Zhao (Sun Yat-sen University Cancer Center)

Abstract: 8081

EGFR-TKI as neoadjuvant treatment in patients with NSCLC with EGFR sensitive mutation: A retrospective real-world analysis.

EGFR-TKI as neoadjuvant therapy in patients with EGFR-sensitive mutated NSCLC: a retrospective real-world analysis

Speaker: Sangtian Liu (The First Affiliated Hospital of Guangzhou Medical University)

Description Number:8082

Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III NSCLC (TRAILBLAZER): Efficacy, safety and feasibility of surgical conversion outcomes from a proof-of-concept, phase 2 trial.

NEOADJUVANT SHR-1701 WITH OR WITHOUT CHEMOTHERAPY IN UNRESECTABLE PHASE III NSCLC: PROOF-OF-CONCEPT TRIAL OF EFFICACY, SAFETY, AND FEASIBILITY OF SURGICAL CONVERSION OUTCOMES IN A PHASE II TRIAL (TRAILBLAZER).

Speaker: Wu Yilong (Guangdong Provincial People's Hospital)

Abstract:8086

Programmed cell death ligand 1 (PD-L1) inhibitors versus programmed cell death 1 (PD-1) inhibitors for the first-line therapy of extensive-stage small cell lung cancer: A propensity score-matched study.

PD-L1 inhibitors versus PD-1 inhibitors in the first-line treatment of ES-SCLC: a propensity score matching study

Speaker: Tian Yaru (Shandong Provincial Cancer Hospital)

Abstract:8089

Tifcemalimab combined with toripalimab and chemotherapy as 1st line treatment for extensive-stage small cell lung cancer (ES-SCLC): A phase Ib/II, open-label study

Tifcemalimab in combination with toripalimab and chemotherapy as first-line treatment for ES-SCLC: a phase Ib/II open-label study

Speaker: Yu Yongfeng (Shanghai Chest Hospital)

Abstract: 8093

ARTEMIS-001: Data from a phase 1a/b study of HS-20093 in patients with relapsed small cell lung cancer (SCLC).

ARTEMIS-001: Data from the Phase Ia/b study of HS-20093 in patients with recurrent SCLC

Speaker: Wang Jie (Cancer Hospital, Chinese Academy of Medical Sciences)

Abstract: 8095

Results of a phase III clinical trial with anti-PDL1 treatment in combination with chemotherapy for extensive stage small cell lung cancer.

Results of a phase III clinical trial of anti-PD-L1 in combination with chemotherapy in the treatment of ES-SCLC

Speaker: Lu Shun (Shanghai Jiao Tong University Chest Hospital)

Abstract: 8098

A randomized phase II study of toripalimab consolidation or observation after concurrent chemoradiotherapy in limited-stage small cell lung cancer.

A randomized phase II study of toripalimab consolidation or observation after concurrent chemoradiotherapy with LS-SCLC

Speaker: Qiu Bo (Sun Yat-sen University Cancer Center)

Abstract: 8100

Serplulimab vs. placebo combined with chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: Extended follow-up results and patient-reported outcomes from the international phase 3 ASTRUM-005 study.

Serplulimab versus placebo in combination with chemotherapy as first-line treatment for ES-SCLC: extended follow-up and patient-reported outcomes from the international ASTRUM-005 Phase III study

Speaker: Ying Cheng (Jilin Provincial Cancer Hospital)

Description No.: 8102

An open-label, multicenter, phase Ib/II study of the ATR inhibitor SC0245 in combination with irinotecan in patients with relapsed and refractory extensive stage small cell lung cancer (ES-SCLC).

An open-label, multicenter, Phase Ib/II study of ATR inhibitor SC0245 in combination with irinotecan in relapsed and refractory ES-SCLC

Speaker: Yu Yongfeng (Shanghai Chest Hospital)

Abstract Number: TPS8117

Efficacy and safety of aumolertinib combined with or without chemotherapy as an adjuvant treatment for stage II-IIIA non-small cell lung cancer following complete tumour resection: The first third-generation EGFR-TKI versus chemotherapy phase III clinical study (APEX).

Efficacy and Safety of Ametinib With or Without Adjuvant Chemotherapy in Phase II-IIIA NSCLC After Complete Resection: A Phase III Clinical Study of the First Third-Generation EGFR-TKI Versus Chemotherapy (APEX)

Speaker: Feng Tan (Cancer Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences)

Abstract Number: TPS8120

Neoadjuvant toripalimab plus chemotherapy for resectable stage II-IIIB non-squamous non-small cell lung cancer with EGFR mutations: A multi-center, multi-cohort, exploratory study.

Neoadjuvant toripalimab in combination with chemotherapy in resectable stage II-IIIB non-squamous NSCLC with EGFR mutations: a multicenter, multi-cohort, exploratory study

Speaker: Sida Cheng (Peking University People's Hospital)

Abstract Number: TPS8131

A phase II exploratory trial of adebrelimab in combination with chemotherapy and concurrent radiotherapy as a first-line treatment for oligo-metastatic extensive-stage small-cell lung cancer.

A phase II exploratory trial of adebrelimab in combination with chemotherapy and concurrent radiotherapy as first-line treatment for oligometastatic ES-SCLC

Speaker: Zhongyi Dong (Department of Radiation Oncology, Nanfang Hospital, Southern Medical University)

Abstract: 8533

A phase Ib/IIa trial to evaluate the safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced NSCLC.

A Phase Ib/IIa trial to evaluate the safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as monotherapy in patients with advanced NSCLC

Speaker: Wu Chunjiao (Jilin Provincial Cancer Hospital)

Abstract No.: 8542

MEK inhibitor combined with RTK inhibitor (trametinib plus anlotinib) in non-G12C KRAS-mutant non-small cell lung cancer: A new strategy.

MEK inhibitor in combination with RTK inhibitor (trametinib plus anlotinib) in the treatment of non-G12C KRAS-mutant NSCLC: a novel strategy

Speaker: Han Baohui (Shanghai Chest Hospital)

Description No.: 8546

Mefatinib as first-line treatment of EGFR sensitizing mutation-positive non-small-cell lung cancer: A phase III efficacy and biomarker study.

Mefatinib as a first-line treatment for EGFR mutation-positive NSCLC: a phase III efficacy and biomarker study

讲者:Jia Yu(上海市肺科医院)

Abstract:8548

Datopotamab deruxtecan (Dato-DXd) in Chinese patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC): Results from the phase 1/2 TROPION-PanTumor02 study.

Dato-DXd in Chinese patients with advanced or metastatic NSCLC: results from the phase I/II TROPION-PanTumor02 study

讲者：Yuping Sun

Abstract: 8554

Phase Ib clinical study of first-line treatment with gefitinib in combination with bevacizumab and chemotherapy in advanced non-squamous non-small cell lung cancer with EGFR mutation.

A Phase Ib clinical study of gefitinib in combination with bevacizumab and chemotherapy in first-line treatment of EGFR-mutated advanced non-squamous NSCLC

Speaker: Xiong Yanjuan (Tianjin Medical University Cancer Hospital)

Summary Number:8557

Efficacy and safety of vebreltinib in patients with advanced NSCLC harboring MET exon 14-skipping: Results of 2.5-year follow-up in KUNPENG.

Efficacy and safety of briitinib in advanced NSCLC with MET exon 14 skipping mutations: results of a 2.5-year follow-up of the KUNPENG study

讲者:Jin-Ji Yan

Abstract No.: 8563

Plasma ctDNA biomarker study in patients with non-small cell lung cancer with EGFR exon 20 insertion mutation treated with sunvozertinib.

Plasma ctDNA biomarkers in patients with NSCLC with EGFR exon 20 insertion mutations in the treatment of suvotinib

讲者:Mengzhao Wang

Abstract: 8587

High-dose furmonertinib in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study.

High-dose fumetinib in patients with EGFR-mutant NSCLC and leptomeningeal metastases: a real-world study

Speaker: Chen Haiyang (Henan Provincial Cancer Hospital)

Abstract: 8604

Efficacy and safety of MCLA-129, an EGFR/c-MET bispecific antibody, in advanced non-small cell lung cancer (NSCLC)

Efficacy and safety of MCLA-129, an EGFR/c-MET bispecific antibody, in advanced NSCLC

Speaker: Wang Jie (Cancer Hospital, Chinese Academy of Medical Sciences)

Abstract:8605

Safety and efficacy of ifebemtinib (IN10018) combined with D-1553 in non-small-cell lung cancer (NSCLC) with KRAS G12C mutation: Results from a phase Ib/II study.

Safety and efficacy of ifebemtinib (IN10018) in combination with D-1553 in the treatment of KRAS G12C-mutant NSCLC: results of a phase Ib/II study

讲者:Zaiqi Wang

Description No.: 8606

Amivantamab plus chemotherapy vs chemotherapy as first-line treatment among patients with EGFR exon 20 insertion–mutated advanced non-small cell lung cancer (NSCLC): PAPILLON Chinese subgroup analysis.

Amivantamab plus chemotherapy versus chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations: a Chinese subgroup analysis of the PAPILLON study

Speaker: TANG Kejing (The First Affiliated Hospital of Sun Yat-sen University)

Abstract: 8609

Efficacy and safety of bronchial arterial chemoembolization (BACE) in combination with tislelizumab for non-small cell lung cancer (NSCLC): A phase II study.

Efficacy and safety of bronchial arterial chemoembolization (BACE) in combination with tislelizumab in NSCLC: a phase II study

Speaker: Duan Xuhua (The First Affiliated Hospital of Zhengzhou University)

Abstract Number: TPS8656

A phase 3 global study of telisotuzumab vedotin versus docetaxel in previously treated patients with c-Met 0verexpressing, EGFR wildtype, locally advanced/metastatic nonsquamous NSCLC (TeliMET NSCLC-01).

telisotuzumab vedotin与多西紫杉醇治疗c-Met过表达、EGFR野生型、局部晚期/转移性非鳞状NSCLC(TeliMET NSCLC-01)患者的III期全球研究

Speaker: Lu Shun (Shanghai Jiao Tong University Chest Hospital)

Abstract Number: TPS8662

TOP: A phase III, multicentre, randomized controlled study comparing osimertinib in combination with carboplatin and pemetrexed to osimertinib monotherapy for untreated patients with advanced non-squamous (Non-sq) non-small cell lung cancer (NSCLC) with concurrent EGFR and TP53 mutations

TOP Study: A Phase III, multicenter, randomized controlled study of osimertinib in combination with carboplatin and pemetrexed versus osimertinib monotherapy in patients with advanced non-squamous NSCLC with EGFR and TP53 mutations

Speaker: Yang Yunpeng (Sun Yat-sen University Cancer Center)

Remark:

Rankings are in no particular order, sorted by abstract number

If there is any omission or any questions, please leave us a message~

Edit: Squid

排版：KIKI、Squid

Execution: Squid

Yimaitong is a professional online doctor platform, and the mission of the platform is to "sense the pulse of the world's medicine and help China's clinical decision-making". Yimaitong has a series of products such as "Clinical Guidelines", "Medication Reference", "Medical Literature King", "Yizhiyuan", "eYantong" and "ePulse", which fully meet the needs of medical workers in clinical decision-making, obtaining new knowledge and improving scientific research efficiency.

This platform aims to deliver more medical information to healthcare professionals. The content published on this platform should not be used as a substitute for professional medical guidance in any way, nor should it be regarded as diagnosis and treatment advice. If such information is used for purposes other than understanding medical information, the platform does not assume relevant responsibilities. This platform does not mean that it agrees with its descriptions and views on the published content. If copyright issues are involved, please contact us, and we will deal with it as soon as possible.